In the present study, we determined that Roblitinib, a representative FGFR4 inhibitor, exerted anti-cancer effects in HCC cells, and these effects can be enhanced by EZH2 inhibitor CPI-169. The gene discussed is EZH2; the disease is hepatocellular carcinoma.